PAVmed (PAVM) stock
PAVM · PAVmed Inc. · NASDAQ
- Market cap
- $9.1M
- Shares out
- 8.0M
What is the latest news on PAVM stock?
8-K - PAVmed Inc. (0001624326) (Filer)
All PAVM newsWhen does PAVmed report earnings?
PAVmed last reported on Nov 13, 2026, the date it announced on Oct 30, 2026. Before that it reported on Aug 14, 2026 and May 15, 2026. On that schedule the next report would come around mid February 2027, with the date usually announced about 2 weeks ahead.
PAVM earnings historyWho owns the most PAVM stock?
Two Seas Capital LP was the largest reported holder of PAVM at the end of Q2 2026, with 461,539 shares worth $2.7 million. Next came First Manhattan Co. LLC. ($2.0 million) and Vanguard Capital Management LLC ($366K). In all, 20 institutions reported $5.6 million of PAVM in their 13F filings.
All PAVM fund holdersFinancial highlights
Full financials- Revenue, TTM
- $148.0K
- Revenue growth
- +410.3%
- Net income, TTM
- -$18.36M
- Net margin
- -12406.8%
- Free cash flow, TTM
- -$4.48M
- Cash
- $3.63M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- SECPAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PAVmed Inc. (0001624326) (Filer)
- PRPAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial ResultsLucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwideVeris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submissionPAVmed engaged with FDA on PortIO and OcterisConference call and webcast to be held today, November 13, at 8:30 AM ESTNEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health Inc. ("Ve
- PRLucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial ResultsEsoGuard® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarterConference call and webcast to be held today, November 12, at 8:30 AM ESTNEW YORK, Nov. 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update and reported financial results for the third quarter ended September 30, 2026. Conference Call and WebcastThe webcast will take plac
- PRLucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive YearNEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has been named a GenomeWeb 2026 Best Places to Work honoree, marking its second consecutive year in the annual program recognizing top workplaces across the life sciences research, diagnostics and precision medicine sectors. "Our team's shared passion and relentless dedication to preventing esophageal cancer are the foundation of our success," said Shaun O'Neil, President and Chief Operating O
- PRLucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 11, 2026 in New York City. Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a panel discussion titled "Promising Oncology Diagnostics Navigating the Reimbursement Roadmap" on Wednesday, November 11, 2026 at 3:30 p.m. ET. The panel will not
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.SCHEDULE 13G/A - PAVmed Inc. (0001624326) (Subject)
- PRLucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® StudyLargest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer testing to date, using the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
- PRPAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, November 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's third quarter 2026 financial
- PRLucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2026 financial results.
- SECSEC Form 8-K filed by PAVmed Inc.8-K - PAVmed Inc. (0001624326) (Filer)
- PRLucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million FinancingLucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rateSeries C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial accelerationNEW YORK, Oct. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The Company also closed a $15.0 million private placement on Octob
- PRLucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysMedicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee ScheduleAMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheckProposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/NCHS ICD-10 Coordination and Maintenance CommitteeNEW YORK, Sept. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced advances in multiple payment, bill
- SECPAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - PAVmed Inc. (0001624326) (Filer)
- SECPAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PAVmed Inc. (0001624326) (Filer)
- PRPAVmed Provides Business Update and Reports Second Quarter 2026 Financial ResultsVeris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable physiological monitor achieved development milestones towards upcoming FDA submissionLucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ®Conference call and webcast to be held today, August 14, at 8:30 AM EDTNEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health In
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.SCHEDULE 13G/A - PAVmed Inc. (0001624326) (Subject)
- SECSEC Form 10-Q filed by PAVmed Inc.10-Q - PAVmed Inc. (0001624326) (Filer)
- PRLucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial ResultsRecognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard ® testsSecured first laboratory benefit manager (LBM) EsoGuard coverage policyConference call and webcast to be held today, August 13, at 8:30 AM EDTNEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026. Conference Call and WebcastThe webcast will take place on Thursday, Aug
- PRLucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA TestConcert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteriaNEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient e
- PRLucid Diagnostics to Participate in Upcoming Investor ConferencesNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that management will participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 10, 2026Location: VirtualCanaccord Genuity 46th Annual Growth Conference Fireside Chat: August 11, 2026, at 11:30 AM ETLocation: Boston, MAThe live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking
- PRPAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's second quarter 2026 financial r
- PRLucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2026 financial results.
- SECSEC Form S-8 filed by PAVmed Inc.S-8 - PAVmed Inc. (0001624326) (Filer)
- SECPAVmed Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PAVmed Inc. (0001624326) (Filer)
- SECPAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PAVmed Inc. (0001624326) (Filer)
- Other4(31%)
- Earnings4(31%)
- SEC Filings3(23%)
- Dividends1(8%)
- 13D/G1(8%)
PAVmed Inc. (PAVM) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for PAVM, including 4 earnings updates, 3 press releases and news items and 1 13D/G filing. The most recent was published Nov 13, 2026.
PAVM FAQ
9 questionsWhat does PAVmed Inc. do?
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable...What is PAVM revenue?
PAVmed Inc. (PAVM) reported $148.0K of revenue for the twelve months ended Sep 30, 2026. That is up 410.3% from the year before. Revenue for fiscal 2025 was $71.0K.Is PAVM profitable?
No. PAVmed Inc. reported a net loss of $18.36M for the twelve months ended Sep 30, 2026.How much cash and debt does PAVM have?
PAVmed Inc. reported $3.63M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PAVM stock trade?
PAVmed Inc. (PAVM) is listed on NASDAQ.What sector and industry is PAVM in?
PAVmed Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did PAVmed Inc. go public?
PAVmed Inc. (PAVM) completed its IPO in 2016.What companies are similar to PAVM?
Notable peers in the same industry include BSX (Boston Scientific Corporation), MDT (Medtronic plc.), LUCD (Lucid Diagnostics Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company). Compare PAVM side-by-side with any of them on Quantisnow.How can I track PAVM on Quantisnow?
Quantisnow aggregates PAVmed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PAVM to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change